Inactive Instrument

Company Incannex Healthcare Australian S.E.

Equities

IHL

AU000000IHL8

Pharmaceuticals

Business Summary

Incannex Healthcare Inc. is a clinical-stage pharmaceutical development company. The Company is developing medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for the treatment of obstructive sleep apnea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, and pain, among other indications. The Company’s diversified portfolio includes 28 distinct research and development (R&D) programs, and six clinical trials underway. Its clinical projects include IHL-42X Obstructive Sleep Apnea, IHL-675A Inflammatory Lung Disease, IHL-675A Rheumatoid Arthritis, IHL-675A Inflammatory Bowel Disease, IHL-216A Concussion and TBI, PSI-GAD Psilocybin for anxiety, MedChew GB Post-herpatic Neuralgia and MedChew -1401 Pain and Spasticity in Multiple Sclerosis.

Number of employees: 3

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 15,873,113 12,454,810 ( 78.46 %) 0 78.46 %

Shareholders

NameEquities%Valuation
1,577,485 9.940 % 6 M $
1,036,512 6.531 % 4 M $
769,721 4.850 % 3 M $
639,549 4.030 % 2 M $
ETF Managers Group LLC
1.982 %
314,609 1.982 % 1 M $
270,847 1.707 % 972 341 $
Vanguard Group, Inc. (Subfiler)
0.7187 %
114,051 0.7187 % 409 443 $
100,000 0.6301 % 359 000 $
Global X Management Co. LLC
0.5151 %
81,747 0.5151 % 293 472 $
AdvisorShares Investments LLC
0.2442 %
38,757 0.2442 % 139 138 $

Company contact information

Incannex Healthcare, Inc.

18 East 50th Street 5th floor

10022, New York

+61 4 2570 3805

http://www.incannex.com
address Incannex Healthcare(IHL)